FREMONT, Calif., March 19 WaferGen Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art geneexpression, genotyping, cell biology and stem cell research systems, todayannounced that David Gelfand, Ph.D., chief scientific officer, will deliver akeynote speech at the Cambridge Healthtech Institute's Fifth Annual MolecularDiagnostics Partnerships in Personalized Medicine Conference. The conferencewill be held March 26-28, 2008, at the Moscone North Convention Center in SanFrancisco, California.
Dr. Gelfand's speech, which will take place at 8:35 a.m. (PST) on Friday,March 28, will celebrate the 25th anniversary of polymerase chain reaction(PCR) and discuss the future of revolutionary technology. He is widelyconsidered one of the world's foremost experts on PCR and DNA sequencing andis credited as the inventor of Thermus aquaticus (Taq) DNA Polymerase for usein PCR.
During his speech, Dr. Gelfand will highlight the key role that PCR hasplayed in the success of the life science industry since its invention,particularly its contribution to the advent of the field of moleculardiagnostics. He will also discuss the key advances in PCR over the past 25years and outline future innovations that will be required for the realizationof the technology's ultimate potential. Finally, Dr. Gelfand will provide anoverview of WaferGen's SmartChip(TM) Real-Time PCR System, the world's firstwhole genome, high throughput gene expression real-time PCR platform.
About the SmartChip(TM) Real-Time PCR System
The SmartChip Real-Time PCR System(TM) is designed as the first wholegenome, high throughput gene expression real-time PCR platform and promises todeliver significant speed and cost advantages to researchers in the geneexpression and genotyping markets. It is estimated that the genetic analysismarket alone (comprised of gene expression and genotyping analysis) hadapproximately $2.4 billion in worldwide revenues in 2006 ($1.74 billion forgene expression and $650 million for genotyping). Total global revenue forthis market is estimated to reach approximately $5.0 billion by 2012.
WaferGen believes the SmartChip Real-Time PCR System will be the firstwhole genome, high throughput gene expression platform to combine thehigh-throughput capability and cost efficiencies of existing microarrays, withthe sensitivity and accuracy of real-time PCR. Specifically, the SmartChipReal-Time PCR System's high density, rapid cycling configuration is expectedto provide industry-leading throughput levels, while offering discovery andvalidation capabilities in a single step. The result will be the ability toconduct gene expression research at a fraction of the time and cost currentlyproduced by existing instrument systems. For example, the company anticipatesthat whole genome assay time may be significantly reduced with the SmartChipReal-Time PCR System as compared to several days or months with microarrays orreal-time PCR, respectively. This decrease in research time has broadeconomic implications across the drug development industry, particularly forpharmaceutical companies seeking avenues for reducing time to market for itstherapeutics. Further, the company believes such throughput will dramaticallyimpact the cost of such assays.
Beyond the significant time and cost advantages, the simplicity of theSmartChip Real-Time PCR System is unparalleled. The system will provide anumber of key ease-of-use features including content-ready chips that canfacilitate experiments without the need for advanced preparation of reagents.The user-friendly SmartChip Real-Time PCR System will accept samples out ofthe box, incorporating nearly all necessary substrates and chemicals. At thesame time, the system will only require a very small sample size as comparedto other technologies and platforms.